lithocholic acid has been researched along with Diabetes Mellitus, Type 2 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, QF; Gao, LX; He, HB; Li, J; Li, JY; Ma, WP; Qiu, WW; Tang, CL; Tang, J; Yang, F | 1 |
| Jia, Y; Jiang, T; Li, S; Ren, Z; Wang, J; Wang, L; Wang, Z; Yu, Y | 1 |
| Chen, X; Fei, Y; Fu, J; Han, J; Sun, L; Zhang, Y; Zhao, L; Zhou, F | 1 |
| Chae, SY; Kim, K; Lee, KC; Lim, SM; Na, DH; Park, EJ; Son, S | 1 |
| Chae, SY; Choi, YG; Jung, SY; Kim, CW; Lee, KC; Lee, S; Son, S | 1 |
| Byun, Y; Chae, SY; Jin, CH; Kim, TH; Lee, KC; Lee, MS; Lee, S; Shin, JH; Son, S; Youn, YS | 1 |
| Andersén, E; Karlaganis, G; Sjövall, J | 1 |
7 other study(ies) available for lithocholic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B.
Topics: Binding Sites; Catalytic Domain; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Kinetics; Lithocholic Acid; Molecular Docking Simulation; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Structure-Activity Relationship | 2012 |
Metabolomics analysis of stool in rats with type 2 diabetes mellitus after single-anastomosis duodenal-ileal bypass with sleeve gastrectomy.
Topics: Alanine; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Anastomosis, Surgical; Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Gastrectomy; Glutamates; Glycated Hemoglobin; Ileum; Isobutyrates; Lithocholic Acid; Obesity, Morbid; Phenylalanine; Phospholipids; Proline; Rats; Streptozocin; Valine | 2022 |
Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drug Stability; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Half-Life; HEK293 Cells; Humans; Hypoglycemic Agents; Liraglutide; Lithocholic Acid; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Serum Albumin, Human; Treatment Outcome; Xenopus Proteins | 2018 |
Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Topics: Animals; Chitosan; Diabetes Mellitus, Type 2; Drug Carriers; Drug Liberation; Exenatide; Hypoglycemic Agents; Lithocholic Acid; Lysine; Mice; Nanoparticles; Particle Size; Peptides; Succinimides; Venoms | 2015 |
Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Topics: Animals; Cell Line, Tumor; Cholic Acids; Deoxycholic Acid; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; In Vitro Techniques; Islets of Langerhans; Lithocholic Acid; Male; Mice; Peptides; Protein Binding; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Serum Albumin; Structure-Activity Relationship; Venoms | 2009 |
Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Hypoglycemic Agents; Lithocholic Acid; Male; Mice; Mice, Inbred C57BL; Peptides; Rats; Rats, Sprague-Dawley; Venoms | 2010 |
Altered bile acid profiles in duodenal bile and urine in diabetic subjects.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Duodenum; Female; Humans; Lithocholic Acid; Male; Middle Aged | 1988 |